According to ACR recommendations, allopurinol is strongly advised as a primary-line urate-reducing medication. Genetic tests is suggested (for the variant known as HLA B*5801) prior to setting up allopurinol as the carriers of this gene are at an elevated hazard of a intense allergic response. A